#1 Clinical Trials Search in Europe

Ripasudil

Ripasudil, a medication used in eye drops, is being studied in several clinical trials for its potential to treat various eye conditions. These trials are investigating how Ripasudil might help patients with corneal problems, especially after eye surgeries or in cases of specific eye diseases. The research aims to understand if Ripasudil can improve vision, reduce corneal swelling, and protect important cells in the eye.

Table of Contents

What is Ripasudil?

Ripasudil, also known by its brand names Glanatec and K-321, is a medication that belongs to a class of drugs called Rho kinase (ROCK) inhibitors. It is primarily used as an eye drop solution to treat various eye conditions[1][2]. Ripasudil was initially approved in Japan in 2014 for treating glaucoma and ocular hypertension (high pressure in the eye)[9]. However, recent research has shown its potential in treating other eye disorders, making it a subject of intense study in ophthalmology.

Conditions Treated with Ripasudil

Ripasudil is being investigated for its effectiveness in treating several eye conditions, including:

  • Fuchs’ Endothelial Corneal Dystrophy (FECD): A condition where the innermost layer of the cornea (the clear front part of the eye) degenerates, causing vision problems[3][5]
  • Corneal Edema: Swelling of the cornea, often occurring after cataract surgery[4]
  • Glaucoma and Ocular Hypertension: Conditions characterized by increased pressure within the eye[9]
  • Retinopathy of Prematurity (ROP): An eye disorder that can occur in premature babies[7]

How Ripasudil Works

Ripasudil works by inhibiting an enzyme called Rho kinase. This action has several beneficial effects on the eye:

  • It helps improve the outflow of fluid from the eye, which can lower intraocular pressure (the pressure inside the eye)[1]
  • It may promote the healing and regeneration of corneal endothelial cells (the innermost layer of the cornea)[10]
  • It could potentially reduce corneal swelling and improve vision in patients with certain corneal disorders[4]

How Ripasudil is Administered

Ripasudil is typically administered as an eye drop solution. The concentration commonly used in clinical trials is 0.4%. The frequency of application can vary depending on the condition being treated and the specific study protocol. Some examples include:

  • Four times daily for 3 months[1]
  • Four times daily for 12 weeks[4]
  • Twice daily for 12 weeks[5]

Ongoing Research and Clinical Trials

Ripasudil is the subject of numerous ongoing clinical trials aimed at exploring its potential benefits for various eye conditions. Some notable studies include:

  • Investigating its effects on corneal endothelial cell density after cataract surgery[1]
  • Evaluating its safety and efficacy in treating corneal edema after cataract surgery[4]
  • Assessing its potential in promoting corneal healing after a procedure called descemetorhexis in patients with Fuchs’ Endothelial Corneal Dystrophy[5]
  • Exploring its use in combination with corneal transplant surgeries[3][8]
  • Investigating its safety and efficacy in premature infants with Retinopathy of Prematurity[7]

Potential Benefits of Ripasudil

Based on ongoing research, Ripasudil may offer several potential benefits:

  • Improved corneal endothelial cell density, which could lead to better corneal health[1]
  • Faster corneal clearing and reduced swelling after certain eye surgeries[4]
  • Potential to improve vision in patients with Fuchs’ Endothelial Corneal Dystrophy[5]
  • Possible reduction in the need for corneal transplants in some patients[9]
  • Potential new treatment option for premature infants with eye complications[7]

Possible Side Effects

While Ripasudil is generally well-tolerated, some potential side effects have been reported in clinical trials. These may include:

  • Conjunctival hyperemia (redness of the eye)[1]
  • Mild gastrointestinal effects[1]

It’s important to note that the safety profile of Ripasudil is still being studied in various ongoing clinical trials. Patients should always consult with their eye doctor about potential risks and benefits before starting any new treatment.

Aspect Details
Main Conditions Studied Fuchs’ Endothelial Dystrophy, Corneal Edema after Cataract Surgery, Retinopathy of Prematurity
Administration Method Eye drops, typically 3-4 times daily
Primary Outcomes Measured Visual acuity, Endothelial Cell Density, Corneal thickness, Corneal edema
Study Durations Vary from 12 weeks to 26 weeks or longer
Comparison Methods Often compared to placebo eye drops
Safety Monitoring Adverse events, eye examinations, intraocular pressure measurements
Special Populations Includes studies on premature infants with ROP
Associated Procedures Some trials involve cataract surgery or descemetorhexis

FAQ

  • What is Ripasudil and what is it being studied for? Ripasudil is a medication used in eye drops. It's being studied in clinical trials for various eye conditions, particularly those affecting the cornea (the clear front part of the eye). Researchers are looking at how it might help after cataract surgery, in cases of Fuchs' Endothelial Dystrophy (a corneal disease), and for other corneal problems.
  • How is Ripasudil given to patients in these trials? In most of the trials, Ripasudil is given as eye drops. The frequency varies, but it's often administered multiple times a day, such as four times daily. Some trials compare Ripasudil to a placebo (a drop without active medication) to see how effective it is.
  • What are the main things researchers are measuring in these trials? Researchers are looking at several outcomes. These include changes in vision (measured by visual acuity tests), the density of certain cells in the cornea (endothelial cells), corneal thickness, and the presence of corneal swelling (edema). They're also monitoring for any side effects of the medication.
  • How long do these clinical trials typically last? The duration of the trials varies, but many last several months. Some trials have treatment periods of 12 weeks, followed by additional follow-up periods. Others extend up to 26 weeks or even longer to assess long-term effects and safety.
  • Are there any known side effects of Ripasudil being studied? While the trials are still ongoing and full safety data isn't available, some studies are specifically looking at potential side effects. For example, one trial is monitoring for conjunctival hyperemia (redness of the eye). As with any medication, researchers carefully track any adverse events reported by participants.

Ongoing Clinical Trials on Ripasudil

  • Study on the Safety and Effectiveness of Ripasudil Eye Drops for Patients with Fuchs Endothelial Corneal Dystrophy After Descemetorhexis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany Spain

  • Study on the Safety and Effectiveness of Ripasudil Eye Drops for Patients with Fuchs Dystrophy After Cataract Surgery

    Not recruiting

    1 1
    Investigated drugs:
    Denmark Germany Spain

Glossary

  • Ripasudil: A medication used in eye drops, also known as K-321 or Glanatec, that is being studied for various eye conditions. It works by inhibiting a specific enzyme in the eye.
  • Fuchs' Endothelial Dystrophy (FED): A progressive eye disease affecting the cornea, causing it to swell and become cloudy, potentially leading to vision problems.
  • Corneal Edema: Swelling of the cornea, often causing blurred vision and discomfort. It can occur after eye surgery or due to certain eye conditions.
  • Endothelial Cell Density (ECD): A measure of the number of endothelial cells in the cornea. These cells are crucial for maintaining corneal clarity.
  • Best Corrected Visual Acuity (BCVA): The best vision a person can achieve with the help of corrective lenses, used as a measure of eye function in clinical trials.
  • Descemetorhexis: A surgical procedure where a layer of the cornea (Descemet's membrane) is removed, sometimes used in the treatment of Fuchs' Endothelial Dystrophy.
  • Placebo: An inactive substance or treatment used in clinical trials to compare with the active drug being tested.
  • Intraocular Pressure (IOP): The fluid pressure inside the eye. High IOP can be a risk factor for glaucoma.
  • Specular Microscopy: A non-invasive imaging technique used to view and analyze the cells of the corneal endothelium.
  • Retinopathy of Prematurity (ROP): An eye disorder that primarily affects premature infants, potentially leading to vision loss if untreated.

References

  1. https://clinicaltrials.gov/study/NCT06048380
  2. https://clinicaltrials.gov/study/NCT05636579
  3. https://clinicaltrials.gov/study/NCT05275972
  4. https://clinicaltrials.gov/study/NCT05528172
  5. https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ripasudil-eye-drops-for-patients-with-fuchs-endothelial-corneal-dystrophy-after-descemetorhexis/
  6. https://clinicaltrials.gov/study/NCT05826353
  7. https://clinicaltrials.gov/study/NCT04621136
  8. https://clinicaltrials.gov/study/NCT05289661
  9. https://clinicaltrials.gov/study/NCT03249337
  10. https://clinicaltrials.gov/study/NCT03813056